OncoExTra
Use
The OncoExTra test helps physicians understand changes to a patient's genomic profile by providing a comprehensive molecular picture of advanced, metastatic, refractory, relapsed, or recurrent solid tumors. This detailed information assists in making informed decisions regarding therapeutic treatment plans. It offers ultra-comprehensive genomic profiling by analyzing both DNA and RNA to detect clinically actionable mutations and fusions. The test further refines therapy selection through patient-matched tumor-normal sequencing, which improves estimates of tumor mutational load and can better predict benefits from immunotherapy with fewer false positives.
Special Instructions
The OncoExTra test is performed at the Genomic Health Phoenix clinical laboratory, which is accredited by the College of American Pathologists (CAP) and certified under Clinical Laboratory Improvement Amendments (CLIA) regulations. Exact Sciences clinical laboratories are qualified for high-complexity clinical testing.
Limitations
The OncoExTra test is not FDA-cleared or approved as an in vitro diagnostic or companion diagnostic for the referenced biomarkers and FDA-approved therapies. The performance characteristics of the test were validated by Genomic Health, Inc., and it may not be suitable for all types of cancers or patient profiles.
Methodology
NGS (WES)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue
Volume
Not provided
Minimum Volume
Not provided